Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Clinics in Kentucky

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

What Kentucky law means for peptide clinics: who may prescribe, whether pharmacies may compound GLP-1 drugs (limited), how to check a clinic, and listings with their verification status.

Kentucky at a glance

Pharmacy regulator
Kentucky Board of Pharmacy
503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async unclear
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Clinics serving Kentucky

No verified clinics serving Kentucky are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Peptide access rules in Kentucky

Yes, but Kentucky's Board of Pharmacy has been unusually explicit about GLP-1 copies. A Kentucky resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from a Kentucky-licensed provider, including by telehealth, which KRS 211.332 defines to include synchronous and asynchronous technology. Kentucky law does not settle whether a first prescription can be issued without a live visit, and KRS 311.597 says an on-line evaluation by questionnaire is not enough. Compounded peptides are available only when eligible under federal 503A rules and dispensed by a Kentucky-permitted pharmacy; Kentucky Board of Pharmacy regulation 201 KAR 2:076 separately prohibits compounding essential copies of commercially available drugs, and the Board's 2025 guidance states that pharmacies in general may not compound semaglutide or tirzepatide. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [13] [18]

Compounded GLP-1 access in Kentucky

The Kentucky Board of Pharmacy's 2025 guidance, "Important Update: Compounding Semaglutide and Tirzepatide," states that in general compounding pharmacies may not compound semaglutide or tirzepatide because they are commercially available, that adding another ingredient such as B12 does not avoid the essentially-a-copy rule, that a lower price is not a valid reason, and that noncompliant compounding may lead to action by both FDA and the Board. The narrow exceptions are a documented patient-specific change that produces a significant difference for that patient, or a return of the drug to the FDA shortage list. [3] [4] [16]

Research use only sellers in Kentucky

Only Kentucky-permitted pharmacies may dispense prescription drugs to Kentucky patients. "Research use only" peptides sold for human injection are unapproved new drugs under federal law regardless of labeling, are not dispensed by a pharmacist, and fall outside Kentucky's compounding regulation. The Kentucky Food, Drug and Cosmetic Act, KRS 217.075, separately bars any person from selling, delivering, holding for sale, or giving away a new drug unless an application for it has become effective under the federal act; its investigational exemption covers only drugs intended solely for investigational use by qualified experts and labeled for investigational use only. [1] [12] [17]

Kentucky notes on specific peptides

  • Semaglutide: Available branded by prescription, including by telehealth. The Kentucky Board of Pharmacy's 2025 guidance says compounding pharmacies in general may not compound semaglutide, and 201 KAR 2:076 makes the essentially-a-copy prohibition enforceable by the Board; adding B12 does not change that. [3] [4]
  • Tirzepatide: Available branded by prescription. The same Kentucky guidance covers tirzepatide: 503A compounding under the shortage allowance ended in 2025, and compounded copies are allowed only for a documented significant patient-specific difference. [3] [16]
  • BPC-157: Not FDA approved and not on the 503A bulks list; its nomination was withdrawn in April 2026. On October 28, 2026 HHS released a draft enforcement discretion policy covering single-ingredient BPC-157 compounded by a state-licensed pharmacy by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's tested substance, with serious adverse events reported to FDA. It is not an FDA approval, is not binding, and does not cover blends such as Wolverine. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). Because it is not commercially available, the essentially-a-copy rule does not apply to it; Kentucky pharmacies apply the federal bulks eligibility test. [4] [14] [15] [19] [20]

How to check a clinic in Kentucky

  1. Confirm the prescribing clinician's license with the Kentucky medical or nursing board.
  2. Ask which pharmacy compounds or dispenses the peptide and check it in the Kentucky Board of Pharmacy license lookup. [1] [3] [4] [11] [13]
  3. Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Kentucky. [1] [12] [17]

Common questions in Kentucky

Do I need an in-person visit to get a prescription by telehealth in Kentucky?

Not necessarily. KRS 211.336 bars state agencies that write telehealth regulations from requiring a provider to be physically present with the patient unless the provider decides it is medically necessary. The Board of Medical Licensure's telemedicine opinion, which is guidance without the force of law, says a physician-patient relationship may be established using telemedicine technologies if the standard of care is met. Kentucky law does not settle whether a visit with no live contact is enough for a first prescription. KRS 311.597 says an electronic, on-line, or telephonic evaluation by questionnaire is inadequate. The prescriber must be licensed in Kentucky. [6] [8] [9] [10]

All peptide legal questions for Kentucky

Sources

  1. [1]Kentucky Board of Pharmacy
  2. [2]Kentucky Board of Medical Licensure
  3. [3]Kentucky Board of Pharmacy: Important update, compounding semaglutide and tirzepatide (2025)2025
  4. [4]201 KAR 2:076, Compounding (Kentucky Board of Pharmacy)
  5. [5]KRS 211.332, Definitions for KRS 211.332 to 211.338 (telehealth) (Kentucky Legislative Research Commission)
  6. [6]KRS 211.336, Duties of agency promulgating administrative regulations relating to telehealth (Kentucky Legislative Research Commission)
  7. [7]900 KAR 12:005, Telehealth terminology and requirements
  8. [8]KRS 311.5975, Duty of treating physician utilizing telehealth (Kentucky Legislative Research Commission)
  9. [9]KRS 311.597, Acts declared to constitute dishonorable, unethical, or unprofessional conduct (Kentucky Legislative Research Commission)
  10. [10]Kentucky Board of Medical Licensure: Board Opinion Regarding the Use of Telemedicine Technologies in the Practice of Medicine (amended September 15, 2022)